Results from the phase I ZIKA-001 study showed that the GLS 5700 vaccine was well tolerated and no significant safety concerns were observed   .
Preclinical data showed that the GLS 5700, zika vaccine induced robust and durable immune responses. The vaccine resulted in seroconversion, or the development of detectable specific antibodies in the blood, and robust and broad T cell responses in all vaccinated mice. GLS 5700 protected 100% of mice from infection, brain damage and death after exposure to the virus. The vaccinated mice were protected from degeneration in the cerebral cortex and hippocampal areas of the brain while un-vaccinated mice showed significant degeneration of the brain after Zika infection. The vaccine was administered using Inovio's CELLECTRA® electroporation delivery technology (Inovio Pharmaceuticals, Form 10-K, March 2016)  .
A single dose of GLS 5700 provided 100% protection from the virus in a study of non-human primates from death and neurological or testicular effects of Zika virus  .
Mice treated with serum samples from GLS 5700 vaccinated subjects from the phase I ZIKA-001 trial, were found to be protected from death and illness in more than 90% of the animals, after they were administered a lethal dose of the zika virus  .
In the phase I ZIKA-001 trial, high levels of binding antibodies were measured in 100% of evaluated subjects, after three doses of GLS 5700 vaccine regimen, and in 95% after two doses of vaccine. Further, neutralizing antibodies were observed in more than 95% of the serum samples that were assayed on neuronal-cell targets. Earlier reported data showed a robust antibody response in 95% and 40% of the volunteers by two doses or a single dose of vaccine, respectively. The parallel-assignment trial enrolled 40 volunteers for the prevention of zika virus infection     .